- Topic
148 Popularity
6k Popularity
25k Popularity
21k Popularity
6k Popularity
5k Popularity
68k Popularity
141k Popularity
70k Popularity
1762k Popularity
- Pin
- #Gate Ranks Top 4 Exchange#
Gate has reached the Top 4 global crypto derivatives exchanges on CoinMarketCap, with a 24-hour trading volume exceeding $15 billion. Enjoy some of the lowest fees in the industry—maker fees as low as 0.015%. Gate is committed to providing users with a more efficient and cost-effective trading experience, making it your top choice for crypto trading!
Start trading now:
👉 Spot Trading: https://www.gate.com/trade
👉 Alpha Trading: https://www.gate.com/alpha
👉 Futures Trading: https://www.gate.com/futures
💬 What derivatives or other products have you recently traded
- 🎉 CandyDrop 5.0: 5 BTC Mega Airdrop is here!
🎁 Total Prize Pool: 5 BTC
📈 Trade any futures pair ≥ 50,000 USDT to earn Candy
👥 Invite friends to unlock more BTC rewards
🗓️ Event Time: June 27, 9:00 – July 11, 9:00 (UTC)
🎯 Max reward per user: 0.01 BTC
👉 Join Now >> https://www.gate.com/candy-drop/detail/BTC-59
⚡ 100% real airdrop — limited time only!
- Gate Alpha 2nd Points Carnival Round 4 Hot Launch! Trade to Share $30,000 MORE & Alpha Points
Trade $MORE to unlock Listing Airdrops + $300K Points Prize Pool!
💰 Total Airdrop Volume: $30,000 MORE, Limited slots—first come, first served!
✅ Total Points: 2 Alpha Points per trade—accumulate points to share the $300K prize pool!
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1342alpha?pid=X&c=MemeBox&ch=vxDB0fQ5
- 📢 $MORE is launching on Gate Alpha!
Users will be able to trade Moonveil ( $MORE ) directly via Gate Alpha — Gate's one-stop on-chain trading portal.
🔥Trade the Hottest On-Chain Assets First
https://www.gate.com/alpha
- 🎁 Gate Alpha Airdrop Alert!
To celebrate the listing of $EGL1 on Gate Alpha @GateioAlpha
A limited-time airdrop campaign is now live — with 149,254 EGL1 up for grabs!
First Come, First Served
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1355?pid=X&ch=0cykUS3i
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company's innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.